Ventripoint Diagnostics Stock Performance
| VPTDF Stock | USD 0.09 0.0007 0.78% |
On a scale of 0 to 100, VentriPoint Diagnostics holds a performance score of 7. The entity has a beta of 0.18, which indicates not very significant fluctuations relative to the market. As returns on the market increase, VentriPoint Diagnostics' returns are expected to increase less than the market. However, during the bear market, the loss of holding VentriPoint Diagnostics is expected to be smaller as well. Please check VentriPoint Diagnostics' maximum drawdown and the relationship between the semi variance and price action indicator , to make a quick decision on whether VentriPoint Diagnostics' existing price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in VentriPoint Diagnostics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental indicators, VentriPoint Diagnostics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
VentriPoint |
VentriPoint Diagnostics Relative Risk vs. Return Landscape
If you would invest 7.32 in VentriPoint Diagnostics on October 30, 2025 and sell it today you would earn a total of 1.77 from holding VentriPoint Diagnostics or generate 24.18% return on investment over 90 days. VentriPoint Diagnostics is currently producing 0.511% returns and takes up 5.6678% volatility of returns over 90 trading days. Put another way, 50% of traded pink sheets are less volatile than VentriPoint, and 90% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
VentriPoint Diagnostics Target Price Odds to finish over Current Price
The tendency of VentriPoint Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.09 | 90 days | 0.09 | about 21.55 |
Based on a normal probability distribution, the odds of VentriPoint Diagnostics to move above the current price in 90 days from now is about 21.55 (This VentriPoint Diagnostics probability density function shows the probability of VentriPoint Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon VentriPoint Diagnostics has a beta of 0.18. This entails as returns on the market go up, VentriPoint Diagnostics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding VentriPoint Diagnostics will be expected to be much smaller as well. Additionally VentriPoint Diagnostics has an alpha of 0.3742, implying that it can generate a 0.37 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). VentriPoint Diagnostics Price Density |
| Price |
Predictive Modules for VentriPoint Diagnostics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as VentriPoint Diagnostics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of VentriPoint Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
VentriPoint Diagnostics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. VentriPoint Diagnostics is not an exception. The market had few large corrections towards the VentriPoint Diagnostics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold VentriPoint Diagnostics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of VentriPoint Diagnostics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.37 | |
β | Beta against Dow Jones | 0.18 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | 0.06 |
VentriPoint Diagnostics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of VentriPoint Diagnostics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for VentriPoint Diagnostics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| VentriPoint Diagnostics is way too risky over 90 days horizon | |
| VentriPoint Diagnostics has some characteristics of a very speculative penny stock | |
| VentriPoint Diagnostics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (3.88 M) with loss before overhead, payroll, taxes, and interest of (6.27 K). | |
| VentriPoint Diagnostics has accumulated about 7.29 M in cash with (3.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. |
VentriPoint Diagnostics Fundamentals Growth
VentriPoint Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of VentriPoint Diagnostics, and VentriPoint Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on VentriPoint Pink Sheet performance.
| Return On Equity | -1.35 | |||
| Return On Asset | -0.64 | |||
| Operating Margin | (124.50) % | |||
| Current Valuation | 28.27 M | |||
| Shares Outstanding | 156.51 M | |||
| Price To Earning | 68.00 X | |||
| Price To Book | 8.27 X | |||
| Price To Sales | 897.04 X | |||
| EBITDA | (3.82 M) | |||
| Cash And Equivalents | 7.29 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 125.38 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (3.15 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 9.54 M | |||
| Retained Earnings | (20.43 M) | |||
| Current Asset | 1.07 M | |||
| Current Liabilities | 3.05 M | |||
About VentriPoint Diagnostics Performance
By analyzing VentriPoint Diagnostics' fundamental ratios, stakeholders can gain valuable insights into VentriPoint Diagnostics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if VentriPoint Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if VentriPoint Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. The company was incorporated in 2004 and is based in Toronto, Canada. Ventripoint Diagnostics is traded on OTC Exchange in the United States.Things to note about VentriPoint Diagnostics performance evaluation
Checking the ongoing alerts about VentriPoint Diagnostics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for VentriPoint Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| VentriPoint Diagnostics is way too risky over 90 days horizon | |
| VentriPoint Diagnostics has some characteristics of a very speculative penny stock | |
| VentriPoint Diagnostics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (3.88 M) with loss before overhead, payroll, taxes, and interest of (6.27 K). | |
| VentriPoint Diagnostics has accumulated about 7.29 M in cash with (3.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. |
- Analyzing VentriPoint Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether VentriPoint Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining VentriPoint Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating VentriPoint Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of VentriPoint Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of VentriPoint Diagnostics' pink sheet. These opinions can provide insight into VentriPoint Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for VentriPoint Pink Sheet analysis
When running VentriPoint Diagnostics' price analysis, check to measure VentriPoint Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VentriPoint Diagnostics is operating at the current time. Most of VentriPoint Diagnostics' value examination focuses on studying past and present price action to predict the probability of VentriPoint Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VentriPoint Diagnostics' price. Additionally, you may evaluate how the addition of VentriPoint Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |